<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04121091</url>
  </required_header>
  <id_info>
    <org_study_id>2019-001907-19</org_study_id>
    <nct_id>NCT04121091</nct_id>
  </id_info>
  <brief_title>Pramipexole to Target &quot;Anhedonic Depression&quot;</brief_title>
  <acronym>PILOT-PRAXOL</acronym>
  <official_title>Pramipexole Augmentation to Target Anhedonia in Depression - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The heterogeneity of depression suggests that different neurocircuits and pathophysiological&#xD;
      mechanisms are involved. Anhedonia - the inability to experience pleasure from, or the lack&#xD;
      of motivation to carry out, usually enjoyable activities - is an endophenotype within the&#xD;
      depression spectrum, with a distinct pathophysiology of dopaminergic mesolimbic projections.&#xD;
      Anhedonia is common in depression and associated with treatment resistance. Pramipexole, an&#xD;
      agonist to the dopamine -receptor 3, is an established treatment of Parkinson's disease.&#xD;
      Based on its mechanism of action, pramipexole might be efficacious in a subtype of depression&#xD;
      characterized by anhedonia and lack of motivation - symptoms linked to dopaminergic&#xD;
      hypofunction. In this proof-of-concept pilot study the investigators test the anti-anhedonic&#xD;
      and antidepressant effects of add-on pramipexole using an &quot;enriched population study design&quot;&#xD;
      including only depressed patients with significant anhedonia. To understand the neurobiology&#xD;
      of anhedonia in depression and to identify treatment predictors, the investigators also do&#xD;
      assessments of anhedonia-related neurocircuitry using (f)MRI and blood biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Actual">March 18, 2021</completion_date>
  <primary_completion_date type="Actual">March 18, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dimensional Anhedonia Rating Scale (DARS) score</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>Change in anhedonia symptoms (total score on the DARS). The range is 0-68, lower score indicating more severe anhedonia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response/remission</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>Montgomery Åsberg Depression Rating Scale (MADRS) reduction 50%, MADRS ≤ 10 respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Åsberg Depression Rating Scale (MADRS) score</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>Change in depression symptoms (total score on the MADRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snaith-Hamilton Anhedonia Pleasure Scale</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>Change in anhedonia symptoms (total score on the Snaith-Hamilton Anhedonia Pleasure Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Motivation and Pleasure Scale</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>Change in motivation/anhedonia symptoms (total score on the the Motivation and Pleasure Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generalized Anxiety Disorder-7</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>Change in anxiety symptoms (total score on the the Generalized Anxiety Disorder-7 scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>Change in insomnia symptoms (total score on the the Insomnia Severity Index scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>Change in fatigue symptoms (total score on the the Fatigue Severity scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apathy Evaluation Scale</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>Change in apathy symptoms (total score on the the The Apathy Evaluation Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory biomarkers</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>The investigators will measure blood levels of Interleukin-6, C-reactive protein, Tumor Necrosis Factor Alpha, and White Blood Cell count at baseline and at study completion. The investigators will test if baseline levels and treatment-associated change in inflammatory markers can predict treatment response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain imaging parameters</measure>
    <time_frame>baseline to week 10 (and baseline data as potential predictor)</time_frame>
    <description>Structural imaging, followed by resting-state functional imaging, diffusion tensor imaging and thereafter the monetary incentive delay task</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Depression, Bipolar</condition>
  <condition>Depression, Unipolar</condition>
  <condition>Dysthymia</condition>
  <condition>Anhedonia</condition>
  <arm_group>
    <arm_group_label>Pramipexole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole Pill</intervention_name>
    <description>Add-on pramipexole</description>
    <arm_group_label>Pramipexole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 and ≤75.&#xD;
&#xD;
          2. Diagnosis of unipolar depression; bipolar disorder in depressive phase or dysthymia.&#xD;
&#xD;
          3. Symptoms of depression; Total-score ≥ 18, measured by Montgomery-Åsberg Depression&#xD;
             Rating Scale (MADRS).&#xD;
&#xD;
          4. Symptoms of anhedonia; Total-score &lt; 27, measured by Dimensional Anhedonia Rating&#xD;
             Scale (DARS).&#xD;
&#xD;
          5. Ongoing treatment with at least one antidepressant drug ≥ 4 weeks without major&#xD;
             changes in dosage. Patients with bipolar disorder must have a mood-stabilizing drug&#xD;
             treatment.&#xD;
&#xD;
          6. Must sign an informed consent. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing pregnancy, breastfeeding or planning for pregnancy.&#xD;
&#xD;
          2. High suicidality assessed by the researcher with medical degree.&#xD;
&#xD;
          3. Ongoing substance use disorder (last 12 month).&#xD;
&#xD;
          4. Diagnosis of psychosis.&#xD;
&#xD;
          5. Ongoing involuntary psychiatric treatment.&#xD;
&#xD;
          6. History of Impulse-control disorder or current ADHD diagnosis.&#xD;
&#xD;
          7. Diagnosis of Intellectual disability, dementia, or other circumstances leading to&#xD;
             difficulties to understand the implications of participating in the study and to give&#xD;
             informed consent.&#xD;
&#xD;
          8. Diagnosis of renal failure (eGFR &lt; 50 ml/min/1,73 m2 ) or severe cardiovascular&#xD;
             disease (defined as symptoms of heart failure NYHA class 2).&#xD;
&#xD;
          9. Recently committed to psychotherapy (during the last 6 weeks) or planning for&#xD;
             psychotherapy during the participation of the study.&#xD;
&#xD;
         10. Ongoing ECT-treatment.&#xD;
&#xD;
         11. Other diseases, disorders or medical treatments that according to the researchers&#xD;
             might influence the results of the study or increases the risks of the study. Such as&#xD;
             Parkinson's disorder, liver failure, cancer not in remission (for at least over a&#xD;
             year).&#xD;
&#xD;
         12. Confirmed or suspected allergy to the active substance or excipients of the drug used&#xD;
             in this study.&#xD;
&#xD;
         13. Committed to other trials&#xD;
&#xD;
         14. Other reasons that according to the researcher might prevent the subject to fulfill&#xD;
             the obligations of the study. For example insufficient drug compliance. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Psychiatry Clinic, Lund, Region Skåne</name>
      <address>
        <city>Lund</city>
        <zip>22358</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Region Skane</investigator_affiliation>
    <investigator_full_name>Daniel Lindqvist</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anhedonia</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Dysthymic Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

